Form 8-K Vitae Pharmaceuticals, For: Aug 04
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Wall St up after tech selloff as yields retreat; Moderna surges
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Francisco Partners to acquire Weave Communications for $650M
Vitae Pharmaceuticals (VTAE) Reports In-Line Q2 EPS
August 4, 2015 4:20 PM EDTVitae Pharmaceuticals (NASDAQ: VTAE) reported Q2 EPS of ($0.45), in-line with the analyst estimate of ($0.45). Revenue for the quarter came in at $161.6 thousand versus the consensus estimate of $80 thousand.
For earnings history and earnings-related data on Vitae Pharmaceuticals (VTAE) click here.
... More